Citius Oncology (CTOR) Fundamentals 2026 — Revenue Analysis | SniperIQ
Citius Oncology (CTOR) is a US-listed Healthcare company in Drug Manufacturers - General with a market capitalization of $56M, trading at $0.60 on the NASDAQ. This SniperIQ fundamentals page covers Citius Oncology's valuation, profitability (net margin -757.6%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Citius Oncology's market cap?
Citius Oncology (CTOR) has a market capitalization of approximately $56M, trading at $0.60 on the NASDAQ. Market cap moves with the live share price.
What is Citius Oncology's P/E ratio?
Citius Oncology's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Citius Oncology?
Citius Oncology runs a net profit margin of -757.6%, a gross margin of 80.1%, and an operating margin of -775.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Citius Oncology pay a dividend?
Citius Oncology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Citius Oncology financially healthy?
Citius Oncology carries a debt-to-equity ratio of 0.11x and a current ratio of 0.50x, with a market beta of 3.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Citius Oncology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Citius Oncology (CTOR) the key facts are: market cap $56M, 52-week range 0.491-2.84. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Citius Oncology's full fundamentals live
Get Citius Oncology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.